Autopsy report · NCT00724425
A Phase 1 Dose Escalation Study of IPI-493
Cause of deathOther
“Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on retaspimycin”
Life of this trial
- Ran for about 3 years before it stopped.
- 53 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Advanced Malignancies
- Interventions
- IPI-493
- Participants
- 53
- Sites
- 5
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.